Additional EUR 32.5 million will support clinical readiness and accelerate lead immuno-virotherapy candidates toward clinical proof-of-concept Abalos Therapeutics announced today an extension
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines
News provided by
Share this article
Share this article
SHANGHAI, March 11, 2021 /PRNewswire/ Delonix Bioworks Ltd. (Delonix), a biotechnology company dedicated to developing the next generation vaccines with synthetic biology approaches, has recently closed a $14 million Series Seed financing led by Boehringer Ingelheim Venture Fund (BIVF) and IDG Capital, with participation from ZhenFund and an undisclosed investor. The financing will be used to accelerate the building of synthetic biology vaccine platforms and advance pipelines of synthetic vaccines to clinical trials.
Based in Shanghai, China, Delonix is working on innovative synthetic biology approaches to develop the next generation medical solutions to address global public health challenges. Delonix s synthetic biology and antigen discovery platforms enable rational design and programming of bact
Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.